JPMorgan Chase & Co. Reiterates Neutral Rating for Phreesia (NYSE:PHR)

Phreesia (NYSE:PHR)‘s stock had its “neutral” rating restated by equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. They presently have a $16.00 target price on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 39.93% from the stock’s previous close.

Several other brokerages have also weighed in on PHR. Royal Bank Of Canada started coverage on Phreesia in a report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective for the company. Needham & Company LLC decreased their target price on Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday. Canaccord Genuity Group lowered their price target on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, December 9th. Truist Financial reissued a “hold” rating and set a $11.00 price target on shares of Phreesia in a research report on Tuesday. Finally, Mizuho reduced their price objective on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 24th. Thirteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Phreesia currently has an average rating of “Moderate Buy” and an average price target of $22.71.

Phreesia Trading Up 4.1%

NYSE PHR opened at $11.43 on Tuesday. The company has a market capitalization of $689.36 million, a price-to-earnings ratio of -114.33 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia has a 12 month low of $10.75 and a 12 month high of $32.76. The company’s fifty day moving average price is $12.51 and its two-hundred day moving average price is $17.68.

Phreesia (NYSE:PHR) last released its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) EPS. As a group, research analysts predict that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider David Linetsky sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $103,863.06. Following the sale, the insider directly owned 231,723 shares in the company, valued at approximately $3,941,608.23. This represents a 2.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the sale, the insider directly owned 834,632 shares in the company, valued at approximately $14,197,090.32. This trade represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 70,358 shares of company stock valued at $1,123,569 over the last three months. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after acquiring an additional 16,309 shares during the last quarter. AQR Capital Management LLC lifted its position in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after purchasing an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after purchasing an additional 2,158 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after purchasing an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reported positive GAAP net income and strong free cash flow for the fiscal year — exceeded internal targets including crossing $100M of Adjusted EBITDA and roughly $50M+ of free cash flow, a proof point for profitability and capital-generation that can support valuation. Phreesia Announces Fourth Quarter Fiscal 2026 Results
• Positive Sentiment: Management highlighted record revenue growth and strategic initiatives on the Q4 call, indicating underlying demand and execution on product/partnership priorities that investors view as longer-term upside. Phreesia Inc (PHR) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic …
• Neutral Sentiment: Full earnings-call transcript is available for detail seekers — useful for investors who want management’s color on drivers, margin improvement, and the AccessOne integration timeline. Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
• Neutral Sentiment: Several analysts revised expectations heading into the print, lowering EPS/forecast assumptions — shows sentiment was already shifting and likely amplified intraday moves. Top Wall Street Forecasters Revamp Phreesia Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Management cut near-term outlook: FY2027 revenue was guided to $510M–$520M and executives warned of headwinds from the network solutions business and integration-related pressure from AccessOne — a driver of the recent sell-off. Phreesia outlines $510M–$520M revenue target for 2027 amid network solutions headwinds and AccessOne integration
• Negative Sentiment: Market reaction: shares plunged after the EPS miss and guidance cut (reports of a ~22% drop and all-time lows in some sessions) — short-term momentum and sentiment risk remain. Phreesia shares tumble 22% on earnings miss, slashed guidance

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.